Latest news articles

Added 18 days ago Drug news

Opdivo did not improve overall survival in ONO-4538-23 study for recurrent ovarian cancer.- Ono + BMS

Ono Pharmaceutical Co., Ltd. announced that Opdivo (nivolumab) Intravenous Infusion a human anti-human programmed cell death-1 (PD-1) monoclonal antibody, did...

Added 29 days ago Drug news

NICE recommends Lynparza for maintenance treatment of relapsed, platinum-sensitive high grade epithelial ovarian, fallopian tube or peritoneal cancer if they have a BRCA1 or BRCA2 mutation (BRCAm).- AstraZeneca + Merck Inc.

AstraZeneca and MSD have announced that NICE has expanded its recommendation for Lynparza (olaparib) tablets for women with relapsed, BRCA-mutated,...

Added 1 month ago Drug news

Lynparza filed sBLA at FDA for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer. AstraZeneca + Merck Inc.

AstraZeneca and MSD Inc., announced that a supplemental New Drug Application for Lynparza (olaparib) in combination with bevacizumab has been...

Search all news articles for Cancer of ovary
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Load more

Guidelines

Management of epithelial ovarian cancer

This guideline provides recommendations based on current evidence for best practice in screening and the role of prophylactic salpingo-oophorectomy; diagnosis; surgical management; chemotherapy; follow up; management...

Added 6 years ago

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up on non-epithelial ovarian cancer covers diagnosis and pathology/molecular biology, staging and risk assessment, treatment plan...

Added 6 years ago

Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up on non-epithelial ovarian cancer covers diagnosis and pathology/molecular biology, staging and risk assessment, treatment plan for early and advanced stages...

Added 7 years ago

Search all guidelines for Cancer of ovary
 

Journal articles

Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.

Rucaparib is a potent inhibitor of poly (ADP-ribose) polymerase (PARP) PARP1, PARP2 and PARP3, and to a lesser extent, PARP4, PARP10, PARP12, PARP15 and PARP16. Study 10 and ARIEL2 evaluated the use of rucaparib as...

Added 5 months ago

How safe is rucaparib in ovarian cancer?

Areas covered: This review will discuss the mechanism of action, clinical efficacy data, and safety of rucaparib as presented from phase 1, 2, and 3 clinical trials.

Added 5 months ago

Rucaparib: A Review in Ovarian Cancer.

Rucaparib (Rubraca®) is a small molecule poly(ADP-ribose) polymerase (PARP) inhibitor with potent activity against PARP-1, -2 and -3. It is approved in the USA and the EU for the treatment of adult patients with BRCA-mutated...

Added 5 months ago

Search all journal articles for Cancer of ovary
 

Clinical trials

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO)

This Phase 1/2 study will evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer.

Added 6 months ago

PH3 Study of IMGN853 vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer (FORWARD I)

This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of IMGN853 to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced...

Added 2 years ago

A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ARIEL3)

Patients enrolled into this study will be stratified into 3 groups based on gene mutations identified in their tumor tissue. The purpose of this study is to evaluate patient response to maintenance treatment with rucaparib versus placebo.

Added 7 years ago

Search all clinical trials for Cancer of ovary
 
Fiona Holland

Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more

What to say and do when someone has cancer

Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.

CME

Ovarian cancer: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
0
Search all CME for Cancer of ovary